awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38140803-CF88555D-2AAA-415B-A078-1C8B0DF7796C
Q38140803-CF88555D-2AAA-415B-A078-1C8B0DF7796C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38140803-CF88555D-2AAA-415B-A078-1C8B0DF7796C
Incretin-based therapies: focus on effects beyond glycemic control alone.
P2860
Q38140803-CF88555D-2AAA-415B-A078-1C8B0DF7796C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38140803-CF88555D-2AAA-415B-A078-1C8B0DF7796C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0c5e90b2a24e00e4282a7b933e707ee0e3783d81
P2860
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.